Results 71 to 80 of about 9,749 (194)

Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation

Saudi Journal of Kidney Diseases and Transplantation, 2014
We conducted a single-center prospective double-arm open-labeled study on kidney transplant patients from 2010 to 2011 to evaluate the efficacy of induction therapy using low, single-dose rabbit-antithymocyte globulin (r-ATG), 1.5 mg/kg on Day 0 (n = 80,
Himanshu V Patel, Vivek B Kute, Aruna V Vanikar, Pankaj R Shah, Manoj R Gumber, Divyesh P Engineer, Hargovind L Trivedi   +6 more
doaj   +1 more source

Is CD25 blockade optimal in kidney transplant patients treated with basiliximab? A target‐mediated drug disposition model

, 2022
International audienceAims Basiliximab, an anti‐CD25 chimeric monoclonal antibody, is approved in prevention of acute kidney transplant rejection. This study aims at investigating target‐mediated pharmacokinetics of basiliximab.
Theodora Bejan‐Angoulvant, Büchler, Matthias, Baron, Christophe, David Ternant, Christophe Baron, Gatault, Philippe, Bejan‐angoulvant, Theodora, Ternant, David, Olivier Le Tilly, Philippe Gatault, Matthias Büchler, Le Tilly, Olivier, Paintaud, Gilles, Gilles Paintaud   +13 more
core   +1 more source

Comparison of clinical outcomes of deceased donor kidney transplantations, with a focus on three induction therapies

Korean Journal of Transplantation, 2019
Background : Graft survival rate of kidney transplantation recipients improves after induction therapy. However, there is no conclusive evidence on which regimen is superior for deceased donor kidney transplantation (DDKT).
Eun Sung Jeong, Kyo Won Lee, Sang Jin Kim, Hee Jin Yoo, Kyung A Kim, Jae Berm Park   +5 more
doaj   +1 more source

Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin

Canadian Journal of Kidney Health and Disease, 2020
Background: Kidney transplant recipients are given induction therapy to rapidly reduce the immune response and prevent rejection. Guidelines recommend that an interleukin-2 receptor antibody (basiliximab) be the first-line agent and that a lymphocyte ...
Rachel Jeong, Robert R. Quinn, Krista L. Lentine, Pietro Ravani, Feng Ye, Patricia Campbell, Kevin Wen, Chris Broscheit, Sita Gourishankar, Ngan N. Lam   +9 more
doaj   +1 more source

Thai Transplant Care Practice Guideline on Immunosuppressive Therapy for Adult Kidney Transplantation

Nephrology, Volume 31, Issue S2, September 2026.
ABSTRACT The Thai Transplantation Society developed these clinical practice guidelines to establish a comprehensive standard for immunosuppressive therapy in adult kidney transplantation. While rooted in evidence‐based medicine, the objective of this document extends beyond local application, serving as a practical model for low‐to‐middle‐income ...
Suwasin Udomkarnjananun, Napun Sutharattanapong, Nuttasith Larpparisuth, Korntip Phonphok, Tanun Ngamvichchukorn, Peenida Skulratanasak, Pitchamon Inkong, Suwikran Wongpraphairot, Opas Traitanon, Piyavadee Homkrailas, Kajohnsak Noppakun, Natavudh Townamchai, on behalf of Thai Transplantation Society   +12 more
wiley   +1 more source

Basiliximab as Induction in Kidney Transplantation: Are There any Real-Life Advantages?

, 2017
Background: Basiliximab is an interleukin-2 receptor antagonist used as induction therapy in kidney transplantation and is believed to reduce acute rejection episode (ARE).
Md Abul Mansur, Tasrina Shamnaz Samdani, Muhammad Abdur Rahim, Sarwar Iqbal, Wasim Md Mohosin Ul Haque, Palash Mitra   +5 more
core   +1 more source

Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients

BMC Nephrology, 2020
Background The efficacy and safety of minimisation of immunosuppression including early steroid withdrawal in kidney transplant recipients treated with Basiliximab induction remains unclear.
Mysore K. Phanish, Richard P. Hull, Peter A. Andrews, Joyce Popoola, Edward J. Kingdon, Iain A. M. MacPhee, for the South West Thames Renal Transplantation Network   +6 more
doaj   +1 more source

Basiliximab [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Basiliximab for the treatment of steroid-resistant ulcerative colitis:Further experience in moderate and severe disease

, 2006
Background: Preliminary data have suggested that interleukin-2 receptor blockade with basiliximab may increase steroid sensitivity. We have previously reported a small case series demonstrating the potential of basiliximab as a novel agent for the ...
Moorghen, M., Valori, R., Creed, T. J., Anderson, J., Hearing, S. D., Smithson, J., Farrant, J. M., Linehan, J., Probert, C. S.J., Shepherd, N. A., Davis, M., Mountford, R. A., Robertson, D., Dayan, C. M.; id_orcid, Crossley, I., Harvey, R., Shaw, I., Panagiotakopoulos, D., Hughes, S., Perry, J., Norman, M. N., Brown, J.   +21 more
core   +2 more sources

Decreasing the steroid rapidly may help to improve the clinical outcomes of patients with intestinal steroid-refractory acute graft-versus-host disease receiving basiliximab treatment

Frontiers in Oncology
Intestinal steroid refractory acute graft-versus-host disease (SR-aGVHD) is the major cause of mortality in allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Cong Cheng, Cong Cheng, Dao-Xing Deng, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Yu-Qian Sun, Xiao-Jun Huang, Xiao-Jun Huang, Xiao-Dong Mo, Xiao-Dong Mo   +16 more
doaj   +1 more source